Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in Type 2 Diabetes Mellitus (T2DM)
Phase: PHASE4
Conditions: Diabetes Mellitus, Type 2
Sponsor: The University of Texas Health Science Center at San Antonio

16-597H, Cersosimo, Protocol, 04-08-20, AMD.DOCX 
1 
 
 
 
 
 
Official Study Title: Effect of Chronic Exenatide Therapy on Beta Cell Function and 
Insulin Sensitivity in T2DM 
 
 
NCT number: NCT02981069 
 
IRB Approval Date: 04-08-2020 
 
Unique Protocol ID: HSC20160597H 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM 

16-597H, Cersosimo, Protocol, 04-08-20, AMD.DOCX 
2 
Study A. 
Subjects: 80 T2DM subjects (age = 18-70 years; BMI = 21-45 kg/m2; male or female) according to the ADA 
criteria will participate in the study. Subjects must be drug naïve and/or on a stable dose (more than 3 months) 
of metformin and/or sulfonylurea and have HbA1c >7.0% and <10.5%. Subjects taking drugs known to affect 
glucose metabolism (other than metformin and sulfonylurea) will be excluded. Other than diabetes, subjects 
must be in good general health as determined by physical exam, medical history, blood chemistries, CBC, TSH,, 
EKG and urinalysis. Only subjects whose body weight has been stable (± 3 lbs) over the preceding three months 
and who do not participate in an excessively heavy exercise program will be included.  Individuals with evidence 
of proliferative diabetic retinopathy, plasma creatinine >1.4 females or >1.5 males will be excluded.  Diabetic 
subjects will be recruited from the South Texas Veterans Health Care System and Texas Diabetes Institute (TDI) 
in San Antonio (Deputy Director = Ralph A. DeFronzo, MD). TDI is the largest institute in the United States that 
provides comprehensive care for ~ 10,000 unduplicated T2DM patients. Therefore, we do not anticipate any 
problem in recruiting the required number of patients for this study.  
Study design: After screening, eligible subjects will receive a measurement of endogenous glucose production 
(EGP) with a prime-continuous infusion of 3-3H-glucose. The EGP measurement will be performed in the morning 
after a 10-12 hour overnight fast and will last 8.5 hours (from 6 AM to 2:30 PM). After a 3.5-hour tracer 
equilibration period, subjects (20 per group) will receive one of the following medications: (i) placebo; (ii) 
exenatide 5 ug subcutaneously; (iii) dapagliflozin (10 mg); and (iv) dapagliflozin 10 mg plus exenatide 5 ug (see 
flow diagram on page 11). Following the test medication at 9:30 AM, blood samples will be drawn every 10-20 
minutes for an additional 5 hours and plasma glucose, insulin, C-peptide, glucagon concentrations and glucose 
specific activity will be measured. One-two weeks after the EGP measurement, participants will 
come back for the Double Tracer Oral Glucose Tolerance Test (DT-OGTT). 
 
Visit 1: Screening. Medical history will be obtained and physical exam will be performed. Blood will be drawn 
for FPG, routine blood chemistries, CBC, lipid profile, HbA1c, and thyroid function. Urinalysis, EKG, 
albumin/creatinine ratio and pregnancy test will be performed.  
Visit 2:  Endogenous Glucose Production Measurement (EGP): The rate of endogenous glucose production 
will be measured with 3-3H-glucose infusion. [3-3H]-glucose infusion will be started at 6 AM and continued until 
2:30 PM (5 hours after drug administration). At 6 AM a catheter will be placed into an anticubital vein and a prime 
(40 uCi x FPG/100)- continuous (0.4 uCi) infusion of  [3-3H]- glucose will be started and continued until 2:30 PM. 
Participant’s hand will be placed in a box heated to 50-60°C (122-140°F). Baseline blood samples will be 
obtained at-210, -60, -50, -45, -40,  -35, -30, -20, -10, and 0. After 3.5 hours of tracer equilibration blood samples 
will be obtained every 10-20 minutes from 9:30 AM to 2:30 PM. Plasma glucose, insulin, C-peptide, glucagon,  
concentrations, and [3-3H]-glucose specific activity will be measured. Urine will be collected from 6 to 9:30 AM 
and from 9:30 AM to 2:30 PM. Urinary volume and glucose concentration will be measured and urinary glucose 
excretion rate calculated. The study will end at 2:30 PM.  
Visit 3:  Double Tracer Oral Glucose Tolerance Test (DT-OGTT):  Within one to two  weeks after the 
measurement of EGP, all subjects will have a 5-hour DT-OGTT with measurement of plasma glucose, insulin (I), 
C-peptide (CP), and glucagon concentrations at -180, -60-, -50-, -45, -40, -35, -30, -20, -10, 0 and every 15-30 
minutes thereafter to obtain a measure of overall glucose tolerance, insulin secretion (ΔCP0-120/ΔG0-120), 
insulin sensitivity (Matsuda index [MI]), beta cell function, (ΔCP0-120/ΔG0-120 x MI), and suppression of plasma 
glucagon concentration (64). At 7 AM a catheter will be placed into an anticubital vein and a prime (25 uCi x 
FPG/100)- continuous (0.25 uCi) infusion of  [3-3H]- glucose will be started and continued until 3 PM Urine will 
be collected from 7 to 10 AM and from 10 AM to 3 PM. Urinary volume and glucose concentration will be 
measured and urinary glucose excretion rate calculated. The study will end at 3 PM.  
 
HbA1c will be measured twice, once on the day of the DTOGTT and once on the day of the EGP measurement. 
 
Data Analysis and Statistical Methods:  The primary end point of the study is the change in EGP during 
Study A.  The difference in the rate of EGP during the last hour of the study (i.e. from 240-300 minutes) between 
drug-treatment and placebo-treatment studies represents the effect of drug treatment on EGP.  The difference 
in EGP will be compared among the 3 drug treatments (exenatide, dapagliflozin, and exenatide plus 
dapagliflozin) with ANOVA.  Post hoc testing will be performed with a Bonferroni correction for multiple 

16-597H, Cersosimo, Protocol, 04-08-20, AMD.DOCX 
3 
comparisons. The following primary comparison will be performed: (i) the change in EGP above baseline 
following dapagliflozin alone versus dapagliflozin/exenatide.  The following secondary comparisons will be made:  
(i) the change in EGP above baseline following exenatide alone versus dapagliflozin/exenatide and (ii) the 
change in EGP above baseline following dapagliflozin alone, exenatide alone, and dapagliflozin/exenatide 
versus the change in EGP following placebo.  Between group comparisons will be made with repeated measures 
ANOVA with time and treatment group as factors.  
Other secondary end points will be: (i) the decrement in the fasting plasma glucose conc at the end of the 
study compared to baseline, (ii) change in plasma glucagon conc at the end of the study compared to baseline; 
and (iii) change in plasma insulin conc at the end of the study compared to baseline. Secondary end points will 
be compared using the same statistical methods described for the primary end point.  
Anticipated Results and Data Interpretation. Consistent with our published data (10), we anticipate that EGP 
will decrease progressively following placebo administration while, after an initial decline, EGP will increase 
progressively following dapagliflozin. We anticipate that plasma glucagon conc will increase and plasma insulin 
concentration will decrease following dapagliflozin administration. We anticipate that a single administration of 
exenatide will cause an increase in plasma insulin conc and a decrease in plasma glucagon conc compared to 
placebo. The increase in plasma insulin and decrease in plasma glucagon conc following exenatide 
administration will result in a greater decline in both EGP and fasting plasma glucose conc compared to placebo.  
Most importantly, we anticipate that the increase in plasma glucagon conc, the decrease in plasma insulin conc, 
and rise in EGP following dapagliflozin administration will be prevented, at least in part, if not totally, when 
exenatide is co-administered with dapagliflozin. Therefore, we anticipate an additive, even synergistic, decrease 
in plasma glucose conc and EGP following co-administration of dapagliflozin plus exenatide compared to either 
drug alone. 
Sample Size Calculation: In our published results (10), the difference in the rate of basal EGP during the last 
hour of EGP measurement in dapagliflozin-treated and placebo-treated individuals was 0.70+0.34 (mean+SD). 
To detect a 50% decrease in the difference at alpha = 0.005 (=0.5/10) (split alpha for up to 10 multiple 
comparisons and a Bonferroni correction) in exenatide plus dapagliflozin versus dapagliflozin alone, we 
computed that 17 subjects in each group provided 90% power. To ensure 17 completers assuming  15% lost 
to follow-up, we have set the sample size at 20 (=17/0.85) in each group.   
 
Study B (see flow sheet below) 
 
Following the measurement of endogenous glucose production [EGP] in Study A, and after the double 
tracer OGTT visit, subjects who receive Byetta will be started on Byetta, 5 ug sc bid, and they will return for a 
follow up visit in 7 days (visit 4) at which time the Byetta will be increased to 10 ug sc bid, if tolerated.  Subjects 
will return at days 14, 21, and 28 (visits 5, 6, and 7).  If the Byetta dose cannot be increased to 10 ug bid because 
of side effects on the day 7 visit, the dose will be advanced on the subsequent visit (i.e., day 14 or 21 or 28), 
side effects permitting.  On the day 28 visit the Double Tracer OGTT will be repeated with Byetta dosing at time 
zero of study (Visit 7). 
 
Subjects who received dapagliflozin will continue on dapagliflozin, 10 mg/day, and will return for follow 
up visits at days 7, 14, and 21.  At the day 28 visit the the DT-OGTT will be repeated.  On the day of DT-OGTT, 
dapagliflozin will be given in the morning prior to the study.  Note that this group will not receive Byetta and, thus, 
will allow us to determine how long the effect of dapagliflozin to increase EGP persists. 
 
Subjects who received dapagliflozin plus Byetta will continue on dapagliflozin and Byetta, and will return 
for follow up visits at days 7, 14, and 21.  At the day 28 visit the DT-OGTT will be repeated.  On the day of the 
DT-OGTT, dapagliflozin will be given in this group will allow us to determine whether the ability of Byetta to inhibit 
the paradoxical rise in EGP observed with dapagliflozin can be blocked on a chronic basis. 
 
Subjects who received the placebo will not be continued forward.  However, these subjects will be allowed 
to be randomized to the Byetta alone, dapagliflozin alone, or Byetta/dapagliflozin groups. 
 
Visits 4, 5 and 6:  Brief Follow Up Visits for interim medical history and compliance with the treatment 
regimen a BMP will be done to check on your kidney function.  
 
 
 
Visit 7:  Double Tracer OGTT will be performed as per Visit 3. 
 
Study C (see flow sheet below). 

16-597H, Cersosimo, Protocol, 04-08-20, AMD.DOCX 
4 
 
Following completion of the OGTT (Visit 7), subjects will be started on Bydureon, 2 mg sc per week.  
Subjects will return of interim follow up visits at weeks 6, 8, 10, 13-14,  (visits 8, 9,10, 11.  During the weeks 16-
18 (visit 12),subjects will have a repeat Double Tracer OGTT (visit 12) will be performed.. 
 
Visits 8, 9, 10, and 11.  Brief Follow Up Visits for interim medical history and compliance with the 
Bydureon regimen. 
 
. 
 
Visit 12:  Double Tracer OGTT will be performed as per Visit 3.  
 
The treatment period could be extended based upon the circumstances (based upon the 
situation of COVID-19 pandemic) until the repeat studies are completed. 
 
Data Analysis:  In Study B, we anticipate that dapagliflozin and Byetta will produce similar reductions 
in HbA1c and that the combination of dapagliflozin plus Byetta will produce an additive/near-additive reduction 
in A1c.  We anticipate that both dapagliflozin and Byetta monotherapy will produce significant weight loss and 
that the combination will produce an additive, even synergistic, effect on weight loss. 
 
We anticipate that that the dapagliflozin-induced rise in EGP will persist after 1 month in T2DM patients 
receiving dapagliflozin monotherapy even though both beta cell function and peripheral insulin sensitivity 
improve.  We expect that Byetta-treated T2DM patients will experience a reduction in both fasting and 
postprandial plasma glucose levels during the DT-OGTT, markedly enhanced beta cell function, improved 
peripheral tissue insulin sensitivity, and reduced fasting and postprandial plasma glucagon concentrations during 
the DT-OGTT.  In T2DM patients receiving combined Byetta/dapagliflozin therapy, we hypothesize that 
exenatide will block the dapagliflozin-induced rise in glucagon secretion and overcome the dapagliflozin-induced 
decrease insulin secretion, resulting in a greater suppression of EGP.  Because we anticipate that Byetta will 
offset the negative effects of dapagliflozin on EGP and on insulin and glucagon secretion, we expect that the 
decline in fasting and postprandial glucose concentrations during the DT-OGTT will be enhanced in T2DM 
subjects receiving combination Byetta/dapagliflozin therapy. 
 
Sample Size Calculation:  In our published results (10), the difference in the rate of basal EGP during 
the last hour of EGP measurement in dapagliflozin-treated and placebo-treated individuals was 0.70±0.34 (mean 
±SD).  To detect a 50% decrease in the difference at alpha = 0.167 (=0.5/3) (split for 3 comparisons and a 
Bonferroni correction) in Byetta plus dapagliflozin versus dapagliflozin alone, we computed that 13 subjects in 
each group will provide 90% power. 
 
 
Data Analysis:  In Study C, we anticipate that dapagliflozin and Bydureon will produce similar reductions 
in HbA1c and that the combination of dapagliflozin plus Bydureon will produce an additive/near-additive reduction 
in A1c.  We anticipate that both dapagliflozin and Bydureon monotherapy will produce significant weight loss and 
that the combination will produce an additive, even synergistic, effect on weight loss. 
 
We anticipate that that the dapagliflozin-induced rise in EGP will persist after 4 months in T2DM patients 
receiving dapagliflozin monotherapy even though both beta cell function and peripheral insulin sensitivity 
improve.  We expect that Bydureon-treated T2DM patients will experience a reduction in both fasting and 
postprandial plasma glucose levels during the OGTT, markedly enhanced beta cell function, improved peripheral 
tissue insulin sensitivity, and reduced fasting and postprandial plasma glucagon concentrations during the DT-
OGTT.  In T2DM patients receiving combined Bydureon-dapagliflozin therapy, we hypothesize that exenatide 
will block the dapagliflozin-induced rise in glucagon secretion and overcome the dapagliflozin-induced decrease 
insulin secretion, resulting in suppression of EGP.  Because we anticipate that Bydureon will offset the negative 
effects of dapagliflozin on EGP and on insulin and glucagon secretion, we expect that the decline in fasting and 
postprandial glucose concentrations during the DT-OGTT will be enhanced in T2DM subjects receiving 
combination Bydureon/dapagliflozin therapy. 
 
Sample Size Calculation:  In our published results (10), the difference in the rate of basal EGP during 
the last hour of EGP measurement in dapagliflozin-treated and placebo-treated individuals was 0.70±0.34 
(mean ±SD).  To detect a 50% decrease in the difference at alpha = 0.167 (=0.5/3) (split for 3 comparisons and 
a Bonferroni correction) in Bydureon plus dapagliflozin versus dapagliflozin alone, we computed that 13 
subjects in each group will provide 90% power. 
 

16-597H, Cersosimo, Protocol, 04-08-20, AMD.DOCX 
5 
STUDY DESIGN 
 
 
Placebo 
Byetta 
Dapagliflozin 
Byetta/Dapagliflozin 
(n=20) 
(n=20) 
(n=20) 
(n=20) 
 
 
3-3H-glucose turnover study/DT-OGTT/A1c x 2 
 
 
 
Byetta, 10 ug bid 
DAPA, 10 mg qd 
Byetta/DAPA 
 
 
4 weeks 
4 weeks 
4 weeks 
 
 
 
 
 
DT-OGTT/A1c x 1 
 
 
 
 
Bydureon, 2 mg  
DAPA, 10 mg qd 
Bydureon/DAPA 
 
Weekly 
 
12 weeks 
12 weeks 
12 weeks 
 
 
 
 
 
DT-OGTT/A1c x 1 
 
 
 COMPARISONS during initial 3-3H-glucose turnover study  
 
 
 
Byetta/Dapa vs Dapa 
 
                     vs Byetta 
 
                     vs Placebo 
 
 
Dapa vs Byetta 
 
          vs Placebo 
 
 
Byetta vs Placebo 
 
 
 
 
 
 

16-597H, Cersosimo, Protocol, 04-08-20, AMD.DOCX 
6 
3-3H-GLUCOSE TURNOVER STUDY 
 
Time 
Glucose 
Insulin 
C-peptide 
Glucagon 
3-3H-glucose 
(min) 
(0.5 ml) 
(1.5 ml) 
(1.5 ml) 
(1.5 ml) 
(2 ml) 
 
-210 
X 
Start 3-3H-glucose AT -210 
-60 
X 
X 
X 
X 
X 
-50 
X 
X 
X 
X 
X 
-45 
X 
 
 
 
X 
-40 
X 
X 
X 
X 
X 
-35 
X 
X 
 
 
X 
-30 
X 
X 
X 
X 
X 
Ingest dapagliflozin at -30 minutes 
-20 
X 
X 
X 
X 
X 
-10 
X 
X 
X 
X 
X 
0 
X 
X 
X 
X 
X 
Inject Byetta at time zero 
15 
X 
X 
X 
X 
X 
30 
X 
X 
X 
X 
X 
45 
X 
X 
X 
X 
X 
60 
X 
X 
X 
X 
X 
75 
X 
 
 
 
X 
90 
X 
X 
X 
X 
X 
105 
X 
 
 
 
X 
120 
X 
X 
X 
X 
X 
135 
X 
 
 
 
X 
150 
X 
X 
X 
X 
X 
165 
X 
 
 
 
X 
180 
X 
X 
X 
X 
X 
200 
X 
 
 
 
X 
220 
X 
X 
X 
X 
X 
240 
X 
 
 
 
X 
260 
X 
X 
X 
X 
X 
280 
X 
X 
X 
X 
X 

16-597H, Cersosimo, Protocol, 04-08-20, AMD.DOCX 
7 
285 
X 
 
 
 
X 
290 
X 
 
 
 
X 
295 
X 
 
 
 
X 
300 
X 
X 
X 
X 
X 
Number 
30 
20 
20 
19 
30 
Volume (ml) 
15 
30 
30 
29 
60 
Total Volume = 164 ml 
 
 
  
 
DOUBLE TRACER ORAL GLUCOSE TOLERANCE TEST (DT-OGTT) 
 
Time 
Glucose 
Insulin 
C-peptide 
Glucagon 
3-3H-glucose 
1-14C-glucose 
(min) 
(0.5 ml) 
(1.5 ml) 
(1.5 ml) 
(1.5 ml) 
(2 ml) 
(4 ml) 
 
-180 
x 
Start tritiated glucose at -180 minutes 
-60 
X 
X 
X 
X 
X 
-50 
X 
 
 
 
X 
-45 
X 
X 
X 
X 
X 
-40 
X 
 
 
 
X 
-35 
X 
 
 
 
X 
-30 
X 
X 
X 
X 
X 
Ingest dapagliflozin at -30 minutes 
-20 
X 
X 
X 
X 
X 
-10 
X 
X 
X 
X 
X 
0 
X 
X 
X 
X 
X 
X 
Inject Byetta at time zero; ingest 75 gm glucose with 14C-glucose at time zero 
15 
X 
X 
X 
X 
X 
X 
30 
X 
X 
X 
X 
X 
X 
45 
X 
X 
X 
X 
X 
X 
60 
X 
X 
X 
X 
X 
X 
75 
X 
X 
X 
 
X 
X 
90 
X 
X 
X 
X 
X 
X 
105 
X 
X 
X 
 
X 
X 
120 
X 
X 
X 
X 
X 
X 

16-597H, Cersosimo, Protocol, 04-08-20, AMD.DOCX 
8 
150 
X 
X 
X 
X 
X 
X 
180 
X 
X 
X 
X 
X 
X 
210 
X 
X 
X 
X 
X 
X 
240 
X 
X 
X 
X 
X 
X 
270 
X 
X 
X 
X 
X 
X 
280 
X 
X 
X 
X 
X 
X 
290 
X 
X 
X 
X 
X 
X 
300 
X 
X 
X 
X 
X 
X 
Number 
24 
22 
22 
20 
25 
17 
Volume (ml) 
12 
33 
33 
30 
50 
68 
Total blood volume = 226 ml 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exclusion Criteria 
1. Presence of significant systemic disease, heart problems including congestive heart failure, unstable 
angina or acute myocardial infarction, current infectious liver disease, acute stroke or transient 
ischemic attacks, history of pancreatitis, urosepsis and pyelonephritis, genital mycotic infections, or 
Type 1 diabetes mellitus  
2. Any hepatic diseases in the past (infectious liver disease, viral hepatitis, toxic hepatic damage, 
jaundice of unknown etiology) or severe hepatic insufficiency and/or significant abnormal liver 
function tests defined as aspartate aminotransferase (AST) >3x upper limit of normal (ULN) and/or 
alanine aminotransferase (ALT) >3x ULN 
3. Renal impairment (e.g., serum creatinine levels ≥1.4 mg/dL for women or ≥1.5 mg/dl for men, or 
eGFR <60 mL/min/1.73 m2) or history of unstable or rapidly progressing renal disease or end stage 
renal disease. 
4. Uncontrolled thyroid disease , Cushing’s syndrome, congenital adrenal hyperplasia or 
hyperprolactinemia 
5. Significantly elevated triglyceride levels (fasting triglyceride > 400 mg/dl), uncontrolled increased LDL-
C 
6. Untreated or poorly controlled hypertension (sitting blood pressure > 160/95 mm Hg) 
7. Use of anti-obesity drugs or weight loss medications (prescription or OTC) and medications known 
to exacerbate glucose tolerance (such as isotretinoin, , GnRH agonists, glucocorticoids, anabolic 
steroids, C-19 progestins) stopped for at least 8 weeks. Use of anti-androgens that act peripherally 
to reduce hirsutism such as 5-alpha reductase inhibitors (finesteride, spironolactone, flutamide) 
stopped for at least 4 weeks 

16-597H, Cersosimo, Protocol, 04-08-20, AMD.DOCX 
9 
8. Prior history of a malignant disease requiring chemotherapy, prior history of bladder cancer 
regardless treatment 
9. Patients at risk for volume depletion due to co-existing conditions or concomitant medications, such 
as loop diuretics should have careful monitoring of their volume status 
10. History of unexplained microscopic or gross hematuria, or microscopic hematuria at visit 1, confirmed 
by a follow-up sample at next scheduled visit. 
11. Presence of hypersensitivity to dapagliflozin or other SGLT2 inhibitors (e.g. anaphylaxis, 
angioedema, exfoliative skin conditions 
12. Known hypersensitivity or contraindications to use GLP1 receptor agonists (exenatide, liraglutide) 
13. Use of , thiazolidinediones, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors  stopped for 
at least 8  weeks. 
 
14. Eating disorders (anorexia, bulimia) or gastrointestinal disorders 
15. Suspected pregnancy (documented negative serum β-hCG test), desiring pregnancy in next 6 
months, breastfeeding, or known pregnancy in last 2 months 
16. Active  history of illicit substance abuse  or significant intake of alcohol 
17. Having a history of bariatric surgery 
18. Patient not willing to use two barrier method  contraception during study period (unless sterilized or 
have an IUD)  
19. Debilitating uncontrolled psychiatric disorder such as psychosis or neurological condition that 
might confound outcome variables 
20. Inability or refusal to comply with protocol 
21. Current participation or participation in an experimental drug study in previous three months 
 
 
Safety 
Definition of adverse events  
An adverse event is the development of an undesirable medical condition or the deterioration of a pre-existing 
medical condition following or during exposure to a pharmaceutical product, whether or not considered causally 
related to the product.   
The term AE is used to include both serious and non-serious AEs. 
Definitions of serious adverse event 
A serious adverse event (SAE) is an AE occurring during any study phase (i.e., run-in, treatment, washout, 
follow-up), that fulfils one or more of the following criteria: 
• 
Results in death 
• 
Is immediately life-threatening 
• 
Requires in-patient hospitalization or prolongation of existing hospitalization  
• 
Results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct 
normal life functions 
• 
Is a congenital abnormality or birth defect 
• 
Is an important medical event that may jeopardize the subject or may require medical intervention to 
prevent one of the outcomes listed above 
The causality of SAEs (their relationship to all study treatment) will be assessed by the investigator(s) and 
communicated to AstraZeneca (AZ). 
Recording of adverse events 
Follow-up of unresolved adverse events 

16-597H, Cersosimo, Protocol, 04-08-20, AMD.DOCX 
10 
Any AEs that are unresolved at the patient’s last AE assessment at the end of the study are followed up by the 
investigator for as long as medically indicated, but without further recording in the CRF. AstraZeneca retains 
the right to request additional information for any subject with ongoing AE(s)/SAE(s) at the end of the study, if 
judged necessary. 
 
 
The following variables will be collected for each AE: 
• 
AE (verbatim) 
• 
The date and time when the AE started and stopped 
• 
Whether the AE is serious or not 
• 
Investigator causality rating against the Investigational Product (yes or no) 
• 
Action taken with regard to investigational product: (AE caused subject’s withdrawal from study (yes 
or no) 
• 
Outcome 
In addition, the following variables will be collected for SAEs: 
• 
Date AE met criteria for serious AE 
• 
Date Investigator became aware of serious AE 
• 
Date of hospitalization 
• 
Date of discharge 
• 
Probable cause of death 
• 
Date of death 
• 
Autopsy performed 
• 
Causality assessment in relation to Study drug(s) 
• 
Causality assessment in relation to Other medication 
• 
Causality assessment in relation to Additional Study Drugs 
• 
Description of AE. 
Causality assessment: 
• 
The Investigator will assess causal relationship between Investigational Product and each Adverse 
Event, and answer ‘yes’ or ‘no’ to the question ‘Do you consider that there is a reasonable possibility 
that the event may have been caused by the investigational product?’ 
• 
For SAEs, a causal relationship will also be assessed for other concomitant medications, study 
procedures, and comparator study drugs.  Note that for SAEs that could be associated with any 
study procedure the causal relationship is implied as ‘yes’. 

16-597H, Cersosimo, Protocol, 04-08-20, AMD.DOCX 
11 
Reporting of serious adverse events  
Investigators and other site personnel will inform the FDA, via a MedWatch/AdEERs form, of any serious or 
unexpected adverse events that occur in accordance with the reporting obligations of 21 CFR 312.32, and will 
concurrently forward all such reports to AZ.  A copy of the MedWatch/AdEERs report will be faxed to AZ at the 
time the event is reported to the FDA.  It is the responsibility of the investigator to compile all necessary 
information and ensure that the FDA receives a report according to the FDA reporting requirement timelines and 
to ensure that these reports are also submitted to AZ at the same time. 
When reporting to AZ, a cover page will accompany the MedWatch/AdEERs form indicating the following: 
• 
Investigator Sponsored Study (ISS)  
• 
The investigator’s name and address 
• 
The trial name/title and AZ ISS reference number 
Investigative site will also indicate, either in the SAE report or in the cover page, the causality of events in relation 
to all study medications and if the SAE is related to disease progression, as determined by the (PI). 
The SAE report and accompanying cover page will be sent by way of fax to AZ’s designated fax line: 1-302-
886-4114 or via email: AEMailboxClinicalTrialTCS@astrazeneca.com. 
Serious adverse events that do not require expedited reporting to the FDA will be reported to AZ using the 
MedDRA coding language for serious adverse events.   
In the case of blinded trials, AZ will request that the Sponsor either provide a copy of the randomization 
code/code break information or unblind those SAEs which require expedited reporting. 
All SAEs will be reported to AZ, whether or not considered causally related to the investigational product.  All 
SAEs will be documented.  The investigator will be responsible for informing the WCMC-Institutional Review 
Board (IRB) of the SAE.  
Safety assessments 
 Safety assessments will consist of monitoring and recording all TEAEs, SAEs, AEs leading to 
discontinuation/withdrawal from study, laboratory evaluation for hematology, blood chemistry, and urine values; 
pregnancy testing; measurement of vital signs and ECGs; and performance of physical examinations.